12 results on '"Kotasek D"'
Search Results
2. Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC).
3. Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer
4. Safety and pharmacokinetics (PK) of motesanib diphosphate in combination with gemcitabine (G) and erlotinib (E) for the treatment of patients (pts) with solid tumors
5. Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC)
6. Effectiveness of darbepoetin alfa 300 mcg every 3 weeks in patients with chemotherapy-induced anemia
7. A novel erythropoiesis-stimulating agent (AMG114) with 131-hour half-life effectively treats chemotherapy-induced anemia when administered as 200 mcg every 3 weeks
8. Combined modality therapy for pancreatic carcinoma: An Australian Pancreatic Cancer Group study of the addition of gemcitabine (G) to concurrent infusional 5-fluorouracil (CI 5FU) and 3D conformal radiotherapy (RT)—Final outcomes
9. Mulicenter phase II study of gemcitabine and carboplatin combination therapy for patients with metastatic carcinoma of unknown primary site: final results
10. Combined modality therapy for pancreatic carcinoma - An Australian Pancreatic Cancer Group study of the addition of gemcitabine to concurrent infusional 5-fluorouracil and 3D conformal radiotherapy
11. Combined modality therapy for pancreatic carcinoma - An Australian Pancreatic Cancer Group study of the addition of gemcitabine to concurrent infusional 5-fluorouracil and 3D conformal radiotherapy
12. Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.